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More than 50% of the world’s population is infected with the bacterium Helicobacter pylori. If left
untreated, infection with H. pylori can cause chronic gastritis and peptic ulcer disease, which may pro-
gress into gastric cancer. Owing to the limited efficacy of anti-H. pylori antibiotic therapy in clinical prac-
tice, the development of a protective vaccine to combat this pathogen has been a tempting goal for
several years. In this study, a chimeric gene coding for the antigenic parts of H. pylori FliD, UreB, VacA,
and CagL was generated and expressed in bacteria and the potential of the resulting fusion protein
(rFUVL) to induce humoral and cellular immune responses and to provide protection against H. pylori
infection was evaluated in mice. Three different immunization adjuvants were tested along with
rFUVL: CpG oligodeoxynucleotides (CpG ODN), Addavax, and Cholera toxin subunit B. Compared to the
control group that had received PBS, vaccinated mice showed significantly higher cellular recall
responses and antigen-specific IgG2a, IgG1, and gastric IgA antibody titers. Importantly, rFUVL immu-
nized mice exhibited a reduction of about three orders of magnitude in their stomach bacterial loads.
Thus, adjuvanted rFUVL might be considered as a promising vaccine candidate for the control of H. pylori
infection.
 2018 Elsevier Ltd. All rights reserved.1. Introduction
H. pylori is a spiral-shaped, microaerophilic, Gram-negative,
flagellated bacterium that colonizes the stomach in more than
50% of the world’s human population [1,2]. Infection with this
bacterium may cause chronic gastritis and peptic ulcers and is also
associated with gastric adenocarcinoma and gastric mucosa-
associated lymphoid tissue lymphoma (MALT) [3]. The strong epi-
demiological relation between H. pylori and distal (non-cardia)
cancer led the World Health Organization Agency to classify H.
pylori as a definite (type I) carcinogen in 1994 [4]. Current
therapies used to eradicate H. pylori include the use of three or four
antibiotics in combination with a proton-pump inhibitor, an
approach that has only been slightly changed over the threedecades since H. pylori was identified [5,6]. Patient compliance,
increasing antibiotic resistance (especially to clarithromycin and
metronidazole), recurrence, and the high cost of the treatment
have led to renewed interest in developing a vaccine to prevent
against H. pylori infection [7–10].
Several H. pylori antigens have been investigated as vaccine
candidates, but the protection provided by each antigen is less than
ideal [11–19]. To improve efficacy, combinations of multiple pro-
tective antigens have been tested. For example, immunization with
three different antigens derived from the vacuolating cytotoxin
(VacA), cytotoxin-associated gene A (CagA), and H. pylori urease
subunit B (UreB), was able to decrease H. pylori colonization in
mice with pre-existing infection [20]. Because of the time-
consuming and difficult process of producing three separate
recombinant proteins, the simultaneous synthesis of antigenic
polypeptides would be highly desirable. However, most of the
reported H. pylori protective antigens are large and expressing
them combined as a fusion protein is hardly feasible. Thus, a
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the potential to provoke robust cellular and humoral immune
responses may be more effective and convenient than a single
recombinant antigen [21–23].
We have recently reported an in silico study in which a chimeric
antigen was designed using four antigenic parts of H. pylori
flagellar hook-associated protein (FliD), UreB, VacA, and
cytotoxin-associated gene L (CagL) proteins [24]. Also, we showed
that vaccination of C57BL/6 mice with recombinant FliD combined
with an adjuvant could stimulate protective immune responses
against H. pylori infection [25]. Therefore, we sought to employ FliD
as the main component of a polyvalent antigen by adding addi-
tional epitopes based on published findings. Since the UreB327–334
B-cell epitope from urease prompts antibody responses that nullify
urease activity and UreB373–385 is considered a novel immunodom-
inant CD4+ T-cell epitope [26,27], the region from UreB covering
both epitopes (UreB327–385) was fused to FliD. In addition, amino
acids 744–805 from VacA, which is deemed a major virulence fac-
tor of H. pylori type I strains [28], contain an MHC class-II binding
peptide that consistently stimulates CD4+ T-cell responses [20].
Thus, this region was also incorporated into the chimeric antigen.
Finally, we have previously shown through a bioinformatics
approach that amino acids 51–100 of the CagL protein
(CagL51–100), a versatile type IV secretion system (T4SS) surface
protein that facilitates the translocation of CagA into host cells
[29], contains numerous domains with antigenic activity [24] and
was therefore also included into the potential vaccine candidate.
Following recombinant expression and purification, the chi-
meric polypeptide was used to immunize mice in combination
with three different adjuvants: CpG ODN, Addavax, and Cholera
toxin subunit B (CTB). The potential of the recombinant fusion pro-
tein to elicit immune responses in C57BL/6 mice and the prophy-
lactic effect of the vaccine against subsequent challenge with H.
pylori was investigated.2. Materials and methods
2.1. Animals
Six- to eight-week-old female C57BL/6 mice were purchased
from the Pasteur Institute of Iran (IPI). All animal procedures were
approved by the Experimental Animal Ethics Committee of the
Kashan University of Medical Science. Mice were acclimated for
one week after arrival before starting the experiments.
2.2. Bacterial strains and growth conditions
The H. pylori strain SS1 (a kind gift from Prof. James G. Fox, Mas-
sachusetts Institute of Technology) was grown on Brucella agar
supplemented with 5% sheep blood, 5 mg/mL trimethoprim,
161.5 mg/mL polymyxin B (Sigma-Aldrich, St. Louis, MO, USA),
10 mg/mL vancomycin (Sigma-Aldrich, St. Louis, MO, USA) and
2.5 mg/mL amphotericin B (Sigma-Aldrich, St. Louis, MO, USA), in
an anaerobic jar with microaerophilic gas generating kit (Merck
Group, Darmstadt, Germany) for 3 days at 37 C. For infection
experiments, bacteria were subcultured in Brucella broth
(Merck Group, Darmstadt, Germany) containing 10 mg/mL van-
comycin and supplemented with 10% Fetal Bovine Serum (FBS)
(Sigma-Aldrich, St. Louis, MO, USA), and grown in microaerophilic
conditions for 72 h at 37 C.
2.3. Construction and expression of recombinant protein
The fuvl chimeric gene design was described previously [24].
Briefly, sequences encoding FliD (1–600), UreB (327–385), VacA(744–805) and CagL (51–100) polypeptides were obtained from
GenBank. To facilitate epitope exposure, flexible glycine-serine
(GS) linkers were inserted between the gene segments. In addition,
the chimeric gene sequence was optimized for expression in
Escherichia coli and a tag comprising six histidine amino acids
was added at the C terminal of the gene to facilitate detection
and purification of the recombinant protein. The fuvl gene synthe-
sis was performed by Biomatik (Cambridge, Ontario, Canada) and
subcloned into the pET26a vector using HindIII and EcoRI
restriction enzymes. Subsequently, E. coli BL21 DE3 cells were
transformed with the pET-fuvl plasmid and expression of the
recombinant fusion protein induced by 1 mM isopropyl-d-1-thioga
lactopyranoside (IPTG) for 4 h at 37 C in the presence of 50 lg/ml
kanamycin. rFUVL was expressed in soluble form and purified
under native conditions. Identity and purity of the recombinant
protein were evaluated by SDS-PAGE and visualized by Coomassie
blue staining and Western blotting [30,31]. Briefly, purified rFUVL
was size-separated by SDS-PAGE and transferred to a PVDF
membrane. Next, the membrane was incubated with anti-6xHis
peroxidase (Roche, Basel, Switzerland) (1/40,000) for 2 h. Finally,
the membrane was developed using 3,30-diaminobenzidine
tetrahydrochloride (Sigma-Aldrich, St. Louis, MO, USA). Contami-
nation of the recombinant protein with endotoxin was prevented
by the inclusion of 0.1% Triton X-114 in all wash buffers used
during purification. Only purified recombinant protein containing
an endotoxin content of less than 0.05 endotoxin units per mg of
protein (evaluated by Limulus amebocyte lysate analysis kit, Lonza,
Basel, Switzerland) was used for further studies [30,31]. The
Bradford method was used to determine the concentration of
recombinant protein [32].
2.4. Immunization and infection with H. pylori
One hundred and sixty mice were randomly divided into eight
groups (n = 18 each). Five groups were immunized subcutaneously
(SC) three times at fifteen-day intervals with 30 mg rFUVL formu-
lated with 20 lg/mouse CpG ODN (CpG, ODN1826 50-TCCAT
GACGTTCCTGACGTT-30, synthesized by TAG Copenhagen, Fred-
eriksberg, Denmark) or Addavax (Invivogen, San Diego, CA, USA),
30 mg rFUVL alone, 20 lg/mouse CpG ODN and Addavax alone, or
only PBS. In addition, to evaluate the protection can be provided
by the killed bacteria, eight mice were received 100 mg formalin-
fixed H. pylori subcutaneously to evaluate the protection can be
provided by the whole lysate of bacteria. To avoid immunizing
with excessive volume, only 100 ml PBS comprising the antigen
and the respective adjuvant was used for each vaccination. The
two remaining groups were orally immunized with rFUVL and 5
lg/mouse CTB (Sigma-Aldrich, St. Louis, MO, USA) or CTB alone
(Table 1). Distilled water was used to dissolve adjuvants.
Forty-five days post initial immunization, five mice from each
group were challenged orally thrice in two-day intervals with 5
 108 colony-forming units (CFUs) of mouse-adapted H. pylori
strain SS1 in 100 ll brain heart infusion broth. In each group, five
mice were bled to obtain sera at days 0, 15, 30, 45, and 75 after the
initial immunization. Another five mice were sacrificed to obtain
tissue and evaluate immune responses including cytokine produc-
tion, IgA secretion, and humoral immune responses on the day of
the challenge. To ensure the observed findings resulted from
immunization treatment, the challenge experiment was repeated
once with the same numbers of mice.
2.5. Protection experiment
To assess whether the vaccination of mice with adjuvanted
rFUVL was able to reduce bacterial load in the stomachs of infected
mice, H. pylori CFUs were quantified four weeks post-infection. For
Table 1
Vaccine formulations and route of application.
Route Vaccine Antigen concentration Adjuvant concentration Total volume Number of mice
Subcutaneous rFUVL + CPG 30 lg 20 lg 100 ll 20
rFUVL + Addavax 30 lg 50 ll 100 ll 20
rFUVL + PBS 30 lg 0 100 ll 20
CpG 0 20 lg 100 ll 20
Addavax 0 50 ll 100 ll 20
Formalin-fixed
H. pylori
SS1 (FF-Hp)
0 100 lg 100 ll 8
PBS 0 0 100 ll 20
Oral rFUVL + CTB 30 lg 5 lg 100 ll 20
CTB 0 5 lg 100 ll 20
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was used; a half section of the stomach from each euthanized
mouse was homogenized, serially diluted, and then cultured as
described above.
2.6. Evaluation of serum antibody responses by ELISA
To specifically evaluate serum IgG1 and IgG2a titers in immu-
nized mice, an enzyme-linked immunosorbent assay (ELISA) was
used. 96-well polystyrene plates (Greiner Bio-One, Frickenhausen,
Germany) were coated with purified rFUVL (5 mg/ml). Upon over-
night incubation, the plates were washed thrice with TBST buffer
(Tris-buffered saline, pH 7.4, containing 0.05% Tween 20) followed
by blocking with 300 ml PBS containing 10% FBS for 2 h at 37 C.
Afterward, the plates were incubated with serial dilutions of
mouse sera for 2 h at room temperature and then washed. HRP-
conjugated goat-anti-mouse IgG1 or IgG2a (BD Pharmingen, USA)
were added to the wells and incubated for another 90 min at 37
C. After the last washing step, specific reactivity was calculated
by the addition of 50 ml/well of the enzyme substrate TMB (Pishtaz
Teb, Tehran, Iran). The reaction was stopped by adding 15 ll of 2 M
H2SO4. Subsequently, the absorbance at 450 nm was measured
using an Anthos 2020 automated plate reader (Anthos Labtec
Instruments, Salzburg, Austria). To determine a cut-off value for
the test, the mean specific OD plus three-fold SD of sera from mice
immunized with PBS was calculated at 1:100 dilution. Serum titers
were obtained as the reciprocal of the last serum dilution providing
an OD higher than the cut-off [33].
To specifically assess stomach mucosal IgA production, a piece
of the mouse stomach was homogenized to obtain a suspension.
Afterward, the supernatant was collected from the suspension by
centrifuging for 20 min at 3000 rpm [34]. The supernatant was
then added in an ELISA plate previously coated with 5 mg rFUVL
and then incubated with anti-mouse IgA (BD Pharmingen, Franklin
Lakes, NJ, USA). Specific activity was evaluated as described above.
2.7. Cytokine responses
We have previously described the assessment of cellular
immune responses [33,35]. Briefly, two weeks after the last immu-
nization, spleens were acquired from euthanized mice under ster-
ile conditions. The excised spleens were sliced into small pieces
and then pressed by the plunger end of a syringe into 0.5% PBS-
EDTA. The mononuclear cells (MNCs) were isolated by Ficoll–
Paque (GE Healthcare, Uppsala, Sweden) from homogenized cells.
An aliquot of 2  106 splenocytes was plated with 2 ml of complete
medium (RPMI 1640) supplemented with 2 mM L-glutamine, 100
U/ml penicillin, 100 lg/ml streptomycin, and 10% heat-inactivated
FBS. Next, 10 lg/ml rFUVL was added to the cells and the mix incu-
bated at 37 C in 5% CO2 for 48 h. To control wells, PBS was addedinstead of the antigen. After 72 h, the supernatants were collected
and stored at 70 C for cytokine assays. Levels of interferon-
gamma (IFN-c), interleukin-17 (IL-17), and interleukin-4 (IL-4)
were determined according to the manufacturer’s instructions
(R&D Systems, Minneapolis, MN, USA).
2.8. XTT assay
The MNCs obtained in 2.7 were rinsed in cold PBS-EDTA and re-
suspended in DMEM without phenol red (Sigma) containing 10%
FBS. The cell concentration was adjusted to 2  106 cells/mL, and
100 ml was added to each well of 96-well culture plates. Cells were
then stimulated with PBS (negative control) or 10 mg/ml FUVL,
rFliD [25], synthetic UreB327–385, VacA744–805 and CagL51–100 (Bio-
matik) or 3 mg/ml of concanavalin A (Con A). All measurements
of cell proliferation were performed in triplicates. After 48 h of
incubation at 37 C in 5% CO2 atmosphere, 100 ml of 1 mg/ml
2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)
carbonyl)-2H-tetrazoliumhydroxide (XTT) (Sigma) containing 25
ml of 5 mM phenazinemethosulfate (PMS) (Sigma) were added to
each well. The optical density was read at 492 nm (Bio-Tek Instru-
ments). The stimulation index (SI) was calculated as the ratio
between the optical density values of stimulated to unstimulated
cells using the following formula:
SI ¼ meanODof stimulatedculture -mean ODof blankcontrol
meanODof unstimulatedculture -meanODof blankcontrol2.9. Histology
Stomach tissues were first fixed in 10% neutral buffered forma-
lin, then embedded in paraffin. The fixed tissues were sliced to 4
mm thickness and then stained with hematoxylin and eosin.
Histopathological damage indexes were calculated by assessing
atrophy grades and inflammation in the fundic and antral mucosa
as described previously [36]. The degree of inflammation was
scored on a scale of 0 to 6: grade 0, absence; grade 2, mild; grade
4, moderate; and grade 6, severe, based on the presence of
polymorphonuclear (acute inflammation) and lymphocytic cells
(chronic inflammation).
2.10. Statistical analysis
Statistical analysis was carried out using SPSS computer soft-
ware, version 16.0. The statistical differences between two groups
were analyzed by t-test and results among several groups were
analyzed by one factor analysis of variance (ANOVA) and Turkey’s
post hoc test. The statistical limit for accepting significance was p
< 0.05. Data were visualized using the GraphPad Prism 7 program.
Fig. 2. Colonization of stomach by H. pylori in immunized mice. C57BL/6 mice were
immunized with three doses of 30 lg rFUVL (days 0, 15, and 30) with CpG ODN,
Addavax, CTB, formalin-fixed H. pylori (FF-Hp) or PBS (eight mice per group).
Control groups received only adjuvants or PBS. Two weeks after final vaccination
(on day 45), mice were challenged orally with H. pylori. Four weeks post-challenge,
levels of gastric H. pylori colonization were determined by quantitative bacterial
culture. Significance (ANOVA) was evaluated with reference to the PBS control; ns:
not significant, *: p < 0.05; ** p < 0.01; *** p < 0.001.
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3.1. Expression and purification of the rFUVL protein
To gain adequate amounts of rFUVL for the protection experi-
ments and immunological analyses, the fuvl gene was designed
and then synthesized commercially. The chimeric gene was sub-
cloned into pET26a+ and E. coli BL21 DE3 cells transformed with
the plasmid. Recombinant fusion protein synthesis was induced
by IPTG and the product purified using Ni-NTA agarose. Identity
and purity of rFUVL was confirmed by SDS-PAGE and Western blot
[31]. Consistent with the molecular weight prediction, recombi-
nant rFUVL had a size of approximately 86 kDa (Fig. 1).
3.2. Vaccination of mice with rFUVL induces protection against H.
pylori
To assess whether immunization with the recombinant protein
vaccine reduces bacterial load in the stomachs of infected mice, we
determined CFUs of H. pylori using quantitative bacterial culture.
Four weeks after challenge, the stomachs of euthanized mice were
minced, homogenized, and cultured. As shown in Fig. 2, higher
levels of protection were observed when an adjuvant, either CpG
ODN, Addavax, or CTB, was used with rFUVL, compared to controls
receiving PBS (p < 0.001), indicating that adjuvants have a crucial
role in eliciting protective immunity in these experiments.
Although sterile immunity was not elicited in any of the mice,
the bacterial load in the rFUVL plus CpG ODN immunized groupFig. 1. Expression and purification of recombinant FUVL. (a) Analysis of rFUVL protein ex
induced by the addition of IPTG to the media. Four hours after induction, the bacteria we
eluted with imidazole. Aliquots of the different fractions were size-separated by SDS-P
marker; lane 2: bacterial lysate after IPTG induction; lane 3: flow-through from the
imidazole; lanes 6 to 8: eluate with buffer containing 40 mM Imidazole; lane 9: eluate w
experiments. (b) Western blot analysis of rFUVL using a monoclonal antibody directed a
rFUVL; lane 3: lysate from untransformed bacteria. The expected size of rFUVL: 86 kDa
referred to the web version of this article.)was three orders of magnitude lower than in the control group
(Fig. 2). Even the immunization of mice with rFUVL alone showed
a significant reduction in CFUs, indicating high immunogenicity of
this chimeric antigen.pression by SDS-PAGE. Protein expression in bacteria transformed with pET-fuvlwas
re harvested, the bacterial lysates run over nickel-NTA columns, and bound proteins
AGE and the resulting gel stained with Coomassie-Blue. Lane 1: molecular weight
nickel-NTA column; lanes 4 and 5: column eluate with buffer containing 20 mM
ith buffer containing 1 M imidazole, which was used as immunogen in subsequent
gainst the C-terminal 6His-tag. Lane 1: molecular weight marker; lane 2: purified
. (For interpretation of the references to colour in this figure legend, the reader is
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humoral and mucosal responses
Specific IgG1 and IgG2 antibody titers produced in mice immu-
nized with rFUVL plus different adjuvants were measured by ELISA
in sera obtained on different days after the initial immunization.
Immunization with rFUVL in PBS induced strong immunoglobulin
G (IgG) responses, in which the IgG1 titers were usually slightly
above those of the IgG2a subtype (Fig. 3). In mice immunized with
rFUVL and CpG ODN or Addavax, the IgG1 titer commenced
increasing during the second week after the first immunization,
peaked after six weeks, and remained elevated until the eleventh
week. Remarkably, a sharp drop in both IgG1 and IgG2a titers
was seen in mice immunized with rFUVL formulated with Addavax
after 75 days. By contrast, high titers of both IgG1 and IgG2a were
seen at day 75 after the first immunization in the group immu-
nized with rFUVL plus CTB. The IgG1/IgG2a ratio was 1–1.7 and
1–2 in the groups that had received CpG ODN and Addavax, respec-
tively, and 0.88–1.5 in mice immunized orally (CTB). These results
indicated that rFUVL formulated with adjuvants elicited a Th1-
biased immune response. To assess whether immunization withFig. 3. Analysis of the rFUVL-specific antibody response in immunized animals. (a) Kin
adjuvants. Animals (five mice per group) were bled retroorbitally on the indicated days,
Titer values represent the mean ± SD of sera from three analyses of five animals each. (
specific IgA titers were analyzed by ELISA. W: Comparison of antigen-specific anti-rFU
adjuvant.
H
: Comparison of anti-rFUVL IgA in mice immunized with rFUVL versus PBS.rFUVL also induced mucosal immune responses, gastric IgA pro-
duction was evaluated for each vaccine candidate. As shown in
Fig. 3, the groups immunized with rFUVL plus adjuvants showed
significantly augmented gastric mucosal IgA titers compared to
the control group that had only received PBS (p < 0.0001).
These findings indicated that combinations of rFUVL with CpG
ODN, Addavax, and CTB adjuvants elicited systemic and mucosal
humoral immune responses.
3.4. Immunization of mice with rFUVL plus adjuvant induces mixed
Th1, Th2, and Th17-type immune responses
To further elucidate the provoked immune responses, spleno-
cytes from mice immunized with rFUVL plus adjuvants, rFUVL
alone, or controls were obtained 45 days after the first immuniza-
tion. After re-stimulation of splenocytes with rFUVL, secretion of
IFN-c, IL-4, and IL-17 was measured by ELISA. As shown in Fig. 4,
the levels of all analyzed cytokines were significantly increased
in mice immunized with rFUVL together with adjuvants as com-
pared to the PBS control group. Splenocytes of mice immunized
with rFUVL alone secreted significantly higher amounts of IFN-c,etics of the IgG1 and IgG2a responses after immunization with rFUVL plus different
and specific IgG1 and IgG2a antibody titers against rFUVL were evaluated by ELISA.
b) Gastric suspensions were collected 45 days post first immunization, and rFUVL-
VL IgG1 and IgG2a in mice immunized with rFUVL formulated with and without
ns: not significant, *: p < 0.05, ***: p < 0.001.
Fig. 4. Cytokine production by splenocytes from immunized mice after re-stimulation with rFUVL. Spleen cells of mice from all groups (five mice per group) were stimulated
in vitro with 10 lg/ml rFUVL for 48 h. Cytokine levels in the culture supernatant were measured by sandwich ELISA. The data are the mean ± SD of five individual mice from
each group tested in duplicates. Significance was assessed between mice immunized with rFUVL ± adjuvants and mice treated with PBS. ns: not significant, ***: p < 0.001.
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results show that rFUVL is capable of provoking Th1, Th2, and
Th17 type immune responses. Notably, there were no apparent dif-
ferences in the patterns of cytokines secreted by splenocytes from
mice immunized with rFUVL combined with any of the adjuvants
(Fig. 4). To characterize the immune response against individual
components of the fusion protein, splenocytes from mice immu-
nized with rFUVL were isolated 45 days after the first immuniza-
tion, incubated with rFUVL, rFliD, UreB327–385, VacA744–805 and
CagL51–100, and lymphocyte proliferation analyzed. In comparison
to the PBS control, splenocytes from mice immunized with adju-
vanted rFUVL showed proliferative responses against all antigen
components (Fig. 5). Such recall responses were not observed in
the mice immunized with adjuvants alone or PBS (data not shown).
These results showed that all antigenic components of the fusion
protein could induce cellular immune responses.
3.5. Immunization with rFUVL plus adjuvants induces stomach tissue
inflammation in infected mice
To determine whether immunization with recombinant rFUVL
induces inflammation in infected tissues, stomachs from mice
were evaluated by histology 30 days after infection with H. pylori.
Histological assessment showed a significant difference in theextent of tissue damage resulting from inflammation between
mice immunized with rFUVL plus adjuvants in comparison to the
control group. These results suggested that immunization with
adjuvanted rFUVL leads to strong recall responses upon infection
with H. pylori SS1 (Fig. 6).
4. Discussion
Vaccine efficacy depends on the immunogenicity of the antigen
(s) and the appropriate activation of the immune system by adju-
vants. In the present study, we used a recombinant fusion protein
containing four antigenic fragments of different H. pylori proteins.
In order to identify the most effective adjuvants and route of appli-
cation, rFUVL was administered either orally or subcutaneously
together with CpG ODN, Addavax, or CTB. It has been shown that
CpG ODNs increase the efficacy of vaccines against infectious dis-
eases and cancer [37], and CTB has been used as an adjuvant when
an antigen is administered nasally or orally [38]. Addavax is a
squalene-based oil-in-water nano-emulsion approved in Europe
for use as an adjuvant; such emulsions are known to elicit both
humoral and cellular immune responses. Addavax has a similar
formulation as MF59 that has been approved for use with flu vac-
cines [39,40]. Compared to the control group, the recombinant
fusion protein caused a significant reduction in bacterial load when
Fig. 5. Proliferative responses of spleen cells from mice immunized with rFUVL plus different adjuvants. C57BL/6 mice were immunized with rFUVL formulated with
Addavac, CpG or CBT. Spleen cells from immunized mice were stimulated in vitro with 10 mg/ml purified rFUVL, rFliD, UreB327–385, VacA744–805, CagL51–100 and 3 mg/ml ConA
for 48 h and the extent of proliferation was assayed by XTT. Each bar represents the stimulation index (SI) calculated as the ratio between the obtained mean absorbance
values of stimulated cells to the unstimulated cells. The data are the mean SI ± SD of five individual mice from each group with three repeats. * p < 0.05; ** p < 0.01; *** p <
0.001.
Fig. 6. Histological analysis of gastric tissue from immunized mice with rFULV.
Gastric tissues were obtained at 75 days post the initial immunization and stained
with hematoxylin and eosin. The degree of inflammation was scored as grade 0:
absence; grade 2, mild; grade 4, moderate; or grade 6, severe based on the presence
of polymorphonuclear (acute inflammation) and lymphocytic cells (chronic
inflammation). Significance was assessed between mice immunized with rFUVL ±
adjuvants and mice treated with PBS. ns: not significant, *: p < 0.05, **: p < 0.01.
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caused the strongest reduction in bacterial load. Consistent with
these findings, UreB formulated with CpG ODN has been shown
to provide protection against H. pylori and to elicit cellular immune
responses against certain epitopes of UreB [41].
Remarkably, both CpG ODN and Addavax based vaccines were
administrated subcutaneously; how subcutaneous administration
is able to elicit immune responses and subsequent protection in
the gastric tissue remains to be addressed. That the subcutaneous
route can be successfully used to immunize mice against H. pylori
infection has also been demonstrated in some recent studies
[22,41–44]. To gain insight into the underlying mechanism, we
looked at the antibody response against rFUVL in immunized miceand found that both antigen-specific IgG1 and IgG2a antibodies
were produced. Since IFN-c and IgG2a are indicators of Th1 type
of immune responses in mice, and synthesis of IgG1 can be con-
trolled by Th2 clones, these findings suggested that the immune
responses elicited by the vaccines were of mixed Th1/Th2 type
[45]. Consistent with this, other investigators have observed mixed
Th1/Th2 responses against a set of H. pylori antigens [13,20,23,46].
Notably, the IgG1/IgG2a ratio also showed that the response
elicited in immunized mice had a strong Th1 bias. While C57BL/6
mice have been described as not having the IgG2a gene and thus
being incapable of producing the IgG2a isotype [47], there are sev-
eral strong reports that these mice are in fact able to produce IgG2a
[48–51].
We next examined the mucosal immune responses elicited by
immunization. To this end, the gastric IgA secretion into the gastric
mucosa and immune mediated inflammation were measured for
each vaccine formulation. Compared to control mice, immuniza-
tion with rFUVL plus CpG ODN, Addavax, or CTB elicited significant
levels of antigen-specific gastric IgA and inflammatory cell infiltra-
tions and apoptotic cells in the stomach. These findings indicate
that immunization with rFUVL plus adjuvant, regardless of
whether delivered subcutaneously or orally, efficiently stimulated
gastric mucosal immune responses.
To further characterize the Th1/Th2 profiles of the provoked
immune responses, cell-mediated immune responses were
measured by evaluating cytokine production after in vitro re-
stimulation of immunized mice splenocytes. Our results showed
that splenocytes from all mice immunized with rFUVL produced
IFN-c, IL-4, and IL-17 upon stimulation with antigen. However,
higher amounts of cytokines were secreted in groups immunized
with rFUVL plus adjuvants than PBS.
Cell-mediated immune responses were assessed in mice immu-
nized with rFUVL formulated with different adjuvants by measur-
ing antigen-specific proliferation and cytokine production of
splenocytes in vitro. Splenocytes frommice immunized with rFUVL
with different adjuvants showed significant levels of proliferation
in vitro in response to stimulation with rFUVL, rFliD, UreB327–385,
VacA744–805 and CagL51–100. Of note, the proliferative response
against rFUVL was higher than against any of its components,
suggesting that several or even all antigen fragments in the fusion
protein elicited cellular immune responses.
A. Ghasemi et al. / Vaccine 36 (2018) 5124–5132 5131Although the precise mechanism by which immunization pro-
vides protection against H. pylori remains to be elucidated, the cru-
cial role of cell-mediated immunity has been established in the
past by showing that protection against H. pylori infection can be
established even in the absence of B cells [52]. Several groups have
also demonstrated that protection depends on the induction of
Th1- or Th2-biased responses [53–55]. In addition, Th17 cells and
their effector cytokines appear to mediate immunity against sev-
eral infections, particularly those caused by extracellular patho-
gens like H. pylori [56]. Th17 immune responses comprise
recruitment of neutrophils, secretion of antimicrobial peptides,
and IL-17-driven Th1-mediated protection [57,58]. Although it
has been shown that Th17 responses support bacterial growth
[59], other studies provided strong evidence for the importance
of Th17 cells and IL-17 in the reduction of bacterial load [36,60].
Notwithstanding the prominent relevance in eradicating or con-
trolling several infectious diseases, vaccines are frequently related
to questioning and condemnation about the side effect [61]. With
regard to the toxicity of the vaccine, we didn’t notice any signs of
fever, weight loss, or other systemic indications of toxicity after
immunization with rFUVL formulated with different adjuvants.
Whether the decrease in bacterial load in our vaccinated ani-
mals was mediated by a single, or an interplay of different types
of immune responses, is currently not known. A comprehensive
analysis of cytokine secretion and production of the antimicrobial
peptides in gastric tissue of mice after challenge with H. pylorimay
shed some light on the mechanisms employed by the immune
system to combat infection. Additional experiments are also
needed to evaluate whether the vaccine efficacy can be further
increased by incorporating additional H. pylori antigens.
Taken together, our findings show that rFUVL is a highly
immunogenic fusion protein that, when combined with adjuvants,
especially CpG ODN, is capable of eliciting complex Th1/Th2/Th17
responses and protective immunity against H. pylori infectionAcknowledgments
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